SuperworthTransMedics price to sales ratio TMDX
Market value divided by revenue over the last twelve months, since 2020.
- Today, Oct 23, 2026
- 3.7×
- 7-year median
- 14.8×
- Against its 7-year history
- 1st
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 3.4× to 47.3×
- Peer median
- 2.3×
TransMedics' price to sales ratio is 3.7× as of Oct 23, 2026.
That is below its 7-year median of 14.8×, lower than on 99% of days in the last 7 years.
Over that time it ranged from 3.4× in May 2026 to 47.3× in Mar 2021.
The median for 4 medical device stocks of a similar size is 2.3×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.7× | 3.4× | 8.7× |
| 2025 | 7.5× | 4.8× | 9.9× |
| 2024 | 5.1× | 5.1× | 16.9× |
| 2023 | 13.4× | 8.2× | 35.0× |
| 2022 | 27.5× | 14.1× | 30.6× |
| 2021 | 18.9× | 18.9× | 47.3× |
| 2020 | 22.5× | 10.6× | 22.5× |
Against its peers
Companies in Medical - Devices nearest TransMedics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| TMDXTransMedics | 3.7× |
| CNMDCONMED | 1.1× |
| ITGRInteger | 2.3× |
| LIVNLivaNova | 3.0× |
| ZBHZimmer Biomet | 2.2× |
| Peer median | 2.3× |
Where TransMedics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on TransMedics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.